Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
Miguel Ángel Arrabal PoloMaría Teresa Melgarejo SeguraYaiza María Yáñez-CastilloAna Morales MartínezManuel Pareja VílchezMiguel ArrabalPublished in: Journal of cancer research and clinical oncology (2023)
Adjuvant treatment with BCG or MMC applied with COMBAT or EMDA does not present differences in the recurrence-free rate and progression at 24 months in our population of patients with intermediate- and high-risk NMBC without CIS.